Servicio de Oncología Médica, Hospital Universitario La Fe, Valencia, Spain.
Clin Transl Oncol. 2010 Nov;12(11):765-9. doi: 10.1007/s12094-010-0593-6.
Diffuse large B-cell non-Hodgkin's lymphoma (LDCGB) is one of the best examples of chemotherapy curable malignant diseases. This "Oncoguía SEOM" summarizes the basic directions of staging and recommended treatment options. The staging study should be thorough and includes clinical, laboratory, diagnostic imaging and nuclear medicine. Treatment depends on patient characteristics and comorbidity and on disease extension and prognostic factors. In localized cases, chemoimmunotherapy (CHOP-R) of short duration, followed by involved-field irradiation is the preferred option. In advanced stages, the association of CHOP-like chemotherapy and Rituximab has been a major breakthrough in terms of cure rate. It is important do not forget the supportive treatment in these patients.
弥漫性大 B 细胞非霍奇金淋巴瘤（LDCGB）是化疗可治愈的恶性疾病的最佳范例之一。本“SEOM 肿瘤学指南”总结了分期的基本方向和推荐的治疗选择。分期研究应该全面，包括临床、实验室、诊断影像学和核医学。治疗取决于患者的特征和合并症，以及疾病的范围和预后因素。在局限性病例中，短疗程的化疗免疫治疗（CHOP-R），随后进行受累野照射是首选。在晚期，CHOP 样化疗联合利妥昔单抗是治愈率的重大突破。重要的是，不要忘记这些患者的支持治疗。
